Serina Therapeutics, Inc. SER
1.43 USD +0.05 (+3.62%)
At closeNov 9, 2026, 4:00 PM EST
1.43 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
1.36 Day range 1.54
1.14 52-week range 4.45
- YTD
- -25.13%
- 1 year
- -63.43%
- Market cap
- 36.32M
- Revenue (ttm)
- 3.16M
- Profit margin
- -232.86%
- EPS (ttm)
- -1.87
- Shares out
- 9.39M
- YTD return
- -25.13%
- 1-year return
- -63.43%
- Volume
- 91.79K
- Avg volume
- 76.64K
- Open
- 1.29
- Previous close
- 1.38
- Day's range
- 1.36 – 1.54
- 52-week range
- 1.14 – 4.45
No chart data for this range yet.
Key statistics
- Enterprise value
- 61.58M
- PEG ratio
- 0.00
- Price / sales
- 16.07
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -53.10%
- Free cash flow
- -7.45M
- Total cash
- 3.19M
- Total debt
- 11.47M
- Return on equity
- 0.00%
- Short % of float
- 0.67%
- 50-day average
- 5.80
- 200-day average
- 8.47
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
SER Revenue — quarterly 0
SER Net income — quarterly -6.36M
SER EPS — quarterly -0.55
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- serinatherapeutics.com
News
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) 
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Your note
Sign in to keep a note on SER — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY GREGORY HUGH | Director | Purchase | Dec 16, 2024 | 67,243 |
| JUVENESCENCE LTD. | Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Mar 13, 2023 | 16,447,500 |
| MINTZ STEVEN MICHAEL | Director | Purchase | Sep 11, 2024 | 0 |
| WEST MICHAEL D | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 9, 2023 | 41,982 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 0.96% | 85,219 | 460.18K | Sep 29, 2024 |
| Waverly Advisors, LLC | 0.76% | 67,492 | 364.46K | Sep 29, 2024 |
| Vanguard Group Inc | 0.50% | 44,500 | 240.30K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.27% | 24,026 | 129.74K | Sep 29, 2024 |
| HighTower Advisors, LLC | 0.25% | 22,434 | 121.14K | Sep 29, 2024 |
| Millennium Management Llc | 0.22% | 19,256 | 103.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.36% | 31,799 | 171.71K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 15,593 | 84.20K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.14% | 12,333 | 66.60K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.09% | 7,900 | 42.66K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.04% | 3,720 | 20.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.03% | 2,592 | 14.00K | Oct 30, 2024 |